Interim results from Mediclinic show that minority shareholders are probably getting a fair deal from the Remgro-led consortium that made an offer of £5.04 per share for their shares. Based on the latest results, the offer equates to a price-earnings ratio of 22 times, while shareholders are bound to appreciate the advantages of having a bird in the hand rather than seeing them flying around the bush.
The scheme of arrangement has received approval from all the relevant authorities in different countries, except in SA – the only uncertainty remaining for shareholders.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: